NOVEL STRIP TEST FOR MEASURING OVULATION

尿17b-雌二醇代谢产物E_1-g和P_d-g的测定 黄体酮，可以定义生育期和决定发生 或排卵失败。他们的测量目前需要 实验室方法，因为e1-g存在于ng/m1水平，而且因为 E1-g浓度的变化非常微妙，需要 半定量。IA，Inc.已经获得了非常令人鼓舞的初步结果 用于区分排卵和非排卵的试纸的研制数据 使用一种创新的技术翻译的E1-g的排卵水平 抗体和抗原结合成视觉上明显的颜色 变化。与使用酶或其他方法测量ng/ml浓度的测试不同 胶体金，这些条将不需要仪器。我们 建议将这项创新技术应用于 开发包含一种手段的e1-g测试条的可行性 校正尿量的变化，以达到准确的 在生育期和周期的其余部分之间的区别。 半量化将通过比较 条带上的颜色以浓度刻度的方式改变 体温计。该方法快速、简便，试条更稳定 而不是使用酶的测试。 建议的商业应用 检测排卵发生或失败的试纸，并定义 肥沃时期将找到兽医应用，并将提供场外交易 一种对人类计划生育和体外试验有用的方法 受精。这项技术可以扩展到包括广泛的范围 激素，药物，代谢物和毒素，提供医生的办公室 筛查、家庭测试、兽医测试和现场测试到位 昂贵的实验室程序。

Measurements of E1-g and Pd-g, urinary metabolites of 17b-estradiol and progesterone, can define the fertile period and determine the occurrence or failure of ovulation. Their measurement currently requires laboratory methods because E1-g is present at ng/m1 levels and because changes in concentrations of E1-g are subtle enough to require semiquantitation. IA, Inc. has obtained very encouraging preliminary data on development of test strips which distinguish ovulatory from non- ovulatory levels of E1-g using an innovative technology which translates binding between antibody and antigen into a visually apparent color change. Unlike tests measuring ng/ml concentrations using enzymes or colloidal gold, these strips will not require instrumentation. We propose to bring this innovative technology to a clear demonstration of feasibility by developing test strips for E1-g which incorporate a means of correcting for variations in urine volume so as to achieve accurate discrimination between the fertile period and the rest of the cycle. Semiquantification will be achieved by comparing the location of the color change on the strip to a concentration scale in the manner of a thermometer. The method will be rapid, simple, and strips more stable than tests employing enzymes. PROPOSED COMMERCIAL APPLICATION Strips detecting occurrence or failure of ovulation, and defining the fertile period will find veterinary applications and will provide an OTC method which will be useful for human family planning and for in vitro fertilization. The technology can be expanded to include a wide range of hormones, drugs, metabolites and toxins, providing physician's office screening, homes testing, veterinary testing, and field testing in place of expensive laboratory procedures.